Basophil Activation Test with Different Polyethylene Glycols in Patients with Suspected PEG Hypersensitivity Reactions

Int J Mol Sci. 2022 Nov 23;23(23):14592. doi: 10.3390/ijms232314592.

Abstract

Allergic reactions to COVID-19 vaccine components are rare but should be considered. Polyethylene glycol (PEG) is responsible for anaphylaxis in mRNA vaccines. Skin tests have been used in the allergological work-up programs for COVID-19 vaccine evaluation. However, the reproducibility of the skin prick test is time-dependent and the reactivity declines over time. Therefore, we combined the administration of the skin tests with the basophil activation test (BAT) using PEG2000, PEG4000 and DMG-PEG2000, where the BAT was considered positive when the percentage of activated basophils was higher than 6%, 5% and 6.5%, for PEG 4000, PEG2000 and DMG-PEG2000, respectively. To this end, among the subjects that underwent allergy counseling at the Allergy Unit of our Institution during the 2020/2021 vaccination campaign, 13 patients had a suggested medical history of PEG/drug hypersensitivity and were enrolled together with 10 healthy donors. Among the enrolled patients 2 out of 13 tested patients were positive to the skin test. The BAT was negative in terms of the percentages of activated basophils in all analyzed samples, but the stimulation index (SI) was higher than 2.5 in 4 out of 13 patients. These data evidenced that, when the SI is higher than 2.5, even in the absence of positivity to BAT, the BAT to PEG may be a useful tool to be coupled to skin tests to evidence even low-grade reactions.

Keywords: COVID-19; allergy testing; basophil activation tests; hypersensitivity; polyethylene glycol; stimulation index.

MeSH terms

  • Anaphylaxis*
  • Basophil Degranulation Test
  • Basophils
  • COVID-19 Vaccines
  • COVID-19*
  • Humans
  • Hypersensitivity* / diagnosis
  • Polyethylene Glycols / adverse effects
  • Reproducibility of Results
  • Skin Tests

Substances

  • COVID-19 Vaccines
  • polyethylene glycol 4000
  • Polyethylene Glycols

Grants and funding

Domenico De Bellis has a PhD fellowship (code: n. 1353889) in the framework of PON RI 2014/2020, I.1-“Innovative PhDs with industrial characterization”, funded by the Italian Ministry of University and Research (MUR), Italy, FSE-FESR.